Skip to content

Abstract A027: Rescuing MYMK/MYMX-Dependent Cell Fusion to Promote Myogenic Differentiation in Rhabdomyosarcoma

Sep 2026 · Cancer Research · Vol 86, pp. A027-A027 · 0 citations

TL;DR

The data indicate that RMS cells express the core myogenic and fusogenic machinery but inefficiently achieve the paired MYMK/MYMX state needed for cell–cell fusion, providing functional evidence that the terminal fusion step is an actionable bottleneck in RMS differentiation.

Abstract

Rhabdomyosarcoma (RMS) arises from a skeletal muscle lineage but fails to complete terminal myogenic differentiation, including cell–cell fusion. Productive cell fusion during skeletal muscle formation requires the coordinated activity of the fusogenic membrane proteins myomaker (MYMK) and myomixer (MYMX). We investigated whether RMS cells are arrested in differentation at a step close to myogenic cell fusion and that restoring balanced MYMK/MYMX expression would rescue cell–cell fusion, promote myogenic differentiation, and reduce tumorigenic behavior. We first assessed fusogen expression in fusion-negative (FN) RD and fusion-positive (FP) Rh30 RMS cells, using normal myoblasts as controls. Western blotting and qPCR showed reciprocal fusogen imbalance where Rh30 exhibited a relatively MYMK-low/MYMX-high signature, whereas RD cells were MYMK-high/MYMX-low. This pattern showed little correction after differentiation, unlike myoblast controls, which induced both fusogens during myotube formation. To confirm the observation of muscle fusogen imbalance in RMS cells, we interrogated 460 publicly available RNA-sequencing data sets. Bulk RNA sequencing showed that FN & FP RMS tumors variably but consistently expressed MYMK, MYMX, MYOD1, and MYOG. We next used single-cell data to assess whether fusogen expression was coordinated within individual cells. Compared with normal developing muscle, differentiated RMS cells were less often positive for both MYMK and MYMX at the same time. MYMK/MYMX double-positive cells represented 20.7% of differentiated RMS cells, compared with 46.6% of human developmental muscle cells and 65.4% of mouse developmental muscle cells. Thus, our data indicate that RMS cells express the core myogenic and fusogenic machinery but inefficiently achieve the paired MYMK/MYMX state needed for cell–cell fusion. We then tested whether restoring fusogen pairing could overcome the block for cell fusion in RMS cells. We generated fusogen rescue models expressing MYMK, MYMX, or MYMK/MYMX. In Rh30 cells, MYMK or MYMK/MYMX overexpression was associated with enlarged multinucleated cells that frequently stained strongly for MyHC. In RD cells, MYMK/MYMX overexpression—but not MYMX alone—produced MyHC-positive multinucleated structures with a more elongated, myotube-like morphology. Furthermore, overexpresion of MYMK or MYMK/MYMX in RD and Rh30 cells was associated with reduced confluency and transiently increased cytotoxicity. Together, these data support a model in which RMS cells fail to fuse because of an imbalance in the expression of MYMK and MYMX during differentiation. Restoring a MYMK-inclusive fusogen state promotes MyHC-positive multinucleation in both FN- and FP-RMS models, providing functional evidence that the terminal fusion step is an actionable bottleneck in RMS differentiation. Ongoing cytoplasmic mixing assays, cell-cycle profiling, and xenograft studies will determine whether these structures represent productive fusion, durable differentiation, and reduced tumorigenic potential. Yahya Almodallal, Douglas Millay. Rescuing MYMK/MYMX-Dependent Cell Fusion to Promote Myogenic Differentiation in Rhabdomyosarcoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Bridging Discovery and Clinical Impact in Pediatric Cancer; 2026 Sep 22-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_1):Abstract nr A027.

View source

Similar papers

Sep 2026

Abstract IA06: Myogenic and neural transcriptional circuitry determines PAX3::FOXO1-driven initiation of rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Alveolar RMS (ARMS) has a poor prognosis and is driven by either t(2;13)(q35;q14) or t(1;13)(p36;q14) translocations resulting in the PAX3::FOXO1 (P3F) and PAX7::FOXO1 (P7F) fusion oncoproteins, respectively. Current in vivo model systems fail t...

Bradley T. Stevens, Yang E. Zhang, Matthew R. Garcia et al. · 0 citations
Open access Oct 2026

Temporal Dynamics of SMARCA4 Loss Define Its Role in Myogenic Differentiation of Alveolar Rhabdomyosarcoma

SMARCA4 (BRG1) is a critical ATPase subunit of canonical BAF complexes and a known long-term dependency in alveolar rhabdomyosarcoma (ARMS). To define the short-term consequences of SMARCA4 loss, we used a doxycycline-inducible shRNA system in Rh4 cells. Doxycycline treatment produced strong SMARCA4 knockdown, yet acut...

C. Jennings, Emma Lashyro, Jiao-Jiao Wang et al. · 0 citations
Open access Nov 2026

Structure-Function Analysis of an Infantile Rhabdomyosarcoma Fusion-Oncogene Reveals Domain Requirements for Tumorigenesis

Rhabdomyosarcoma is a pediatric soft-tissue sarcoma that reflects impaired skeletal muscle differentiation. Spindle cell/sclerosing rhabdomyosarcoma is a histological subtype found in children and adults. In children under two, spindle cell rhabdomyosarcoma is genetically driven by fusion-oncogenes of transcription fac...

Chinmay S. Sankhe, Delia Calderon, C. Taslim et al. · 0 citations
Sep 2026

Abstract A016: Polyploid giant cancer cells secrete Interferon-beta to induce chemoresistant cell states in fusion-negative rhabdomyosarcoma

Fusion-negative rhabdomyosarcoma (FN-RMS) is a childhood muscle cancer where relapse and refractory disease lead to poor outcomes. Our group has recently shown that FN-RMS is a cancer stem cell (CSC) disease and that these CD44+/CD90+/EGFR+ cells likely contribute to therapy-resistance, yet the precise mechanisms gov...

S. Mathavarajah, Tiffany C. Y. Eng, Elisa J. Quantin et al. · 0 citations
Open access Oct 2026

Phosphorylation of CARM1 at Ser572 preserves muscle stem cell self-renewal by restricting premature myogenic commitment

Skeletal muscle regeneration depends on satellite cells, which must balance myogenic commitment with self-renewal to maintain regenerative capacity throughout life. The methyltransferase CARM1 is a key regulator of satellite cell fate, acting through methylation of PAX7 to promote Myf5 expression and myogenic commitmen...

C. VanGenderen, Rebecca Robertson, Jules A. Granet et al. · 0 citations
Open access Oct 2026

Anti-Nucleolin Aptamer iSN04 Inhibits Alveolar Rhabdomyosarcoma Cell Growth by Inducing Myogenic Differentiation

Rhabdomyosarcoma (RMS) is a muscle-derived soft tissue tumor that retains myogenic potential. Novel drugs for RMS are strongly needed because the standard chemotherapeutic agents for RMS, including vincristine (VCR), have marginally improved the survival rate of high-risk patients for several decades. An anti-nucleolin...

Yoshihiro Saitoh, Tomohide Takaya · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.